Literature DB >> 6476820

An immobilized microbial heparinase for blood deheparinization.

R J Linhardt, C L Cooney, D Tapper, C A Zannetos, A K Larsen, R Langer.   

Abstract

A new medical application of an immobilized microbial enzyme is described. Extracorporeal devices require systemic heparin administration to prevent thrombus formation; however, the use of heparin often leads to serious hemorrhagic complications. Heparinase isolated from Flavobacterium has been immobilized and used in a fluidized bed reactor to eliminate heparin from blood passing through an extracorporeal circuit both in vitro and in vivo. This paper discusses the stepwise development of this heparinase reactor including: (1) improvements in the fermentation resulting in an inexpensive large-scale source of heparinase without the addition of the previously required inducer, heparin; (2) the use of batch processes to adapt previous purification schemes to large-scale heparinase production and the subsequent purification of heparinase to a single SDS-PAGE banding protein; (3) the immobilization of heparinase with a 91% activity recovery and good stability, (4) the design and successful testing of a fluidized bed reactor containing immobilized heparinase in the removal of clinically used quantities of heparin from both human blood in vitro and canine blood in vivo; and (5) the initiation of animal studies focusing on the toxicology of heparinase-derived heparin degradation products and the short and long term effects of exposure to these products and to heparinase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6476820     DOI: 10.1007/bf02798373

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  20 in total

1.  Thrombocytopenia in extracorporeal circulation (ECC). II: Bubble oxygenator versus artificial kidney.

Authors:  J C de Jong; C T Smit Sibinga; C R Wildevuur
Journal:  Trans Am Soc Artif Intern Organs       Date:  1975

2.  Quantitative forward mutation assay in Salmonella typhimurium using 8-azaguanine resistance as a genetic marker.

Authors:  T R Skopek; H L Liber; J J Krolewski; W G Thilly
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Clinical trial of maintenance sequential ultrafiltration and dialysis (UFD).

Authors:  S Glabman; R Geronemus; B von Albertini; T Kahn; G Moutoussis; J P Bosch
Journal:  Trans Am Soc Artif Intern Organs       Date:  1979

4.  Sequential degradation of heparin in Flavobacterium heparinum. Purification and properties of five enzymes involved in heparin degradation.

Authors:  C P Dietrich; M E Silva; Y M Michelacci
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

5.  Semipermeable microcapsules containing catalase for enzyme replacement in acatalasaemic mice.

Authors:  T M Chang; M J Poznansky
Journal:  Nature       Date:  1968-04-20       Impact factor: 49.962

6.  Mode of action of heparin lyase on heparin.

Authors:  R J Linhardt; G L Fitzgerald; C L Cooney; R Langer
Journal:  Biochim Biophys Acta       Date:  1982-04-03

7.  The use of proteic and enzymatic coatings and-or membranes for oxygenators.

Authors:  G Broun; D Thomas; D Domurado; E Selegny
Journal:  Trans Am Soc Artif Intern Organs       Date:  1971

8.  Differential anticoagulant activity of heparin fragments prepared using microbial heparinase.

Authors:  R J Linhardt; A Grant; C L Cooney; R Langer
Journal:  J Biol Chem       Date:  1982-07-10       Impact factor: 5.157

9.  An enzymatic system for removing heparin in extracorporeal therapy.

Authors:  R Langer; R J Linhardt; S Hoffberg; A K Larsen; C L Cooney; D Tapper; M Klein
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

10.  Phenylalanine depletion for the management of phenylketonuria: use of enzyme reactors with immobilized enzymes.

Authors:  C M Ambrus; J L Ambrus; C Horvath; H Pedersen; S Sharma; C Kant; E Mirand; R Guthrie; T Paul
Journal:  Science       Date:  1978-09-01       Impact factor: 47.728

View more
  10 in total

1.  Oral heparin results in the appearance of heparin fragments in the plasma of rats.

Authors:  A K Larsen; D P Lund; R Langer; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

Review 2.  Polysaccharide lyases.

Authors:  R J Linhardt; P M Galliher; C L Cooney
Journal:  Appl Biochem Biotechnol       Date:  1986-04       Impact factor: 2.926

3.  Immobilization alters heparin cleaving properties of heparinase I.

Authors:  Indu Bhushan; Alhumaidi Alabbas; Balagurunathan Kuberan; Ram B Gupta; Umesh R Desai
Journal:  Glycobiology       Date:  2017-11-01       Impact factor: 4.313

4.  Cloning and expression of heparinase I gene from Flavobacterium heparinum.

Authors:  R Sasisekharan; M Bulmer; K W Moremen; C L Cooney; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  Determination of the pKa of glucuronic acid and the carboxy groups of heparin by 13C-nuclear-magnetic-resonance spectroscopy.

Authors:  H M Wang; D Loganathan; R J Linhardt
Journal:  Biochem J       Date:  1991-09-15       Impact factor: 3.857

6.  Fractionation of heparin-derived oligosaccharides by gradient polyacrylamide-gel electrophoresis.

Authors:  K G Rice; M K Rottink; R J Linhardt
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

7.  An investigation of heparinase immobilization.

Authors:  H Bernstein; V C Yang; R Langer
Journal:  Appl Biochem Biotechnol       Date:  1987 Sep-Dec       Impact factor: 2.926

8.  Structure of heparin-derived tetrasaccharides.

Authors:  Z M Merchant; Y S Kim; K G Rice; R J Linhardt
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

9.  Sulfur regulation of heparinase and sulfatases in Flavobacterium heparinum.

Authors:  E C Cerbelaud; L J Conway; P M Galliher; R S Langer; C L Cooney
Journal:  Appl Environ Microbiol       Date:  1986-03       Impact factor: 4.792

10.  Structure-based engineering of heparinase I with improved specific activity for degrading heparin.

Authors:  Chuan Zhang; Bao-Cheng Yang; Wen-Ting Liu; Zhong-Yuan Li; Ya-Jian Song; Tong-Cun Zhang; Xue-Gang Luo
Journal:  BMC Biotechnol       Date:  2019-08-09       Impact factor: 2.563

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.